Clinical management of aggressive fibromatosis/desmoid tumour

Bibliography

• Alman BA, Li C, Pajerski ME, et al. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997;151:329-34
   PubMed Web of Science ®Google Scholar
• Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. editors. World Health Organization classification of tumours of soft tissue and bone. 4th edition. IARC Press, Lyon; 2013
   Google Scholar
• Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999;17:158-67
   PubMed Web of Science ®Google Scholar
• Gronchi A, Colombo C, Le Péchoux C, et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm – a position paper from the Italian and the French Sarcoma Group. Ann Oncol 2014;25:578-83
   PubMed Web of Science ®Google Scholar
• Meazza C, Bisogno G, Gronchi A, et al. Aggressive fibromatosis in children and adolescents: the Italian experience. Cancer 2010;116:233-40
   PubMed Web of Science ®Google Scholar
• Fisher C, Thway K. Aggressive fibromatosis. Pathology 2014;46:135-40
   PubMed Web of Science ®Google Scholar
• Bonvalot S, Ternès N, Fiore M, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol 2013;20:4096-102
   PubMed Web of Science ®Google Scholar
• Phillips SR, A’Hern R, Thomas JM. Aggressive fibromatosis of the abdominal wall, limbs and limb girdles. Br J Surg 2004;91:1624-9
   PubMed Web of Science ®Google Scholar
• Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009;16:2587-93
   PubMed Web of Science ®Google Scholar
• Bonvalot S, Desai A, Coppola S, et al. The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol 2012;23(Suppl 10):x158-66
   PubMed Web of Science ®Google Scholar
• Johner A, Tiwari P, Zetler P, et al. Abdominal wall desmoid tumors associated with pregnancy: current concepts. Expert Rev Anticancer Ther 2009;9:1675-82
   PubMed Web of Science ®Google Scholar
• Castellazzi G, Vanel D, Le Cesne A, et al. Can the MRI signal of aggressive fibromatosis be used to predict its behavior? Eur J Radiol 2009;69:222-9
   PubMed Web of Science ®Google Scholar
• Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-80
   PubMed Web of Science ®Google Scholar
• Lazar AJ, Calonje E, Grayson W, et al. Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin. J Cutan Pathol 2005;32:148-57
   PubMed Web of Science ®Google Scholar
• Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005;18:S19-32
   PubMed Web of Science ®Google Scholar
• Oliva E, Sarrió D, Brachtel EF, et al. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary. J Pathol 2006;208:708-13
   PubMed Web of Science ®Google Scholar
• Johnson V, Volikos E, Halford SE, et al. Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome. Gut 2005;54:264-7
   PubMed Web of Science ®Google Scholar
• Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008;27:6920-9
   PubMed Web of Science ®Google Scholar
• Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008;173:1518-27
   PubMed Web of Science ®Google Scholar
• Amary MF, Pauwels P, Meulemans E, et al. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool. Am J Surg Pathol 2007;31(9):1299-309
   PubMed Web of Science ®Google Scholar
• Mace J, Sybil Biermann J, Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373-9
   PubMed Web of Science ®Google Scholar
• Kurtz JE, Asmane I, Voegeli AC, et al. A V530I Mutation in c-KIT Exon 10 is associated to imatinib response in extraabdominal aggressive fibromatosis. Sarcoma 2010;2010:458156
   PubMedGoogle Scholar
• Miettinen M. Are desmoid tumors kit positive? Am J Surg Pathol 2001;25:549-50
   PubMed Web of Science ®Google Scholar
• Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002;117:188-93
   PubMed Web of Science ®Google Scholar
• Leithner A, Gapp M, Radl R, et al. Immunohistochemical analysis of desmoid tumours. J Clin Pathol 2005;58:1152-6
   PubMed Web of Science ®Google Scholar
• Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006;24:1195-203
   PubMed Web of Science ®Google Scholar
• Liegl B, Leithner A, Bauernhofer T, et al. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours? Histopathology 2006;49:576-81
   PubMed Web of Science ®Google Scholar
• Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 2011;22:452-7
   PubMed Web of Science ®Google Scholar
• Häyry P, Reitamo JJ, Vihko R, et al. The desmoid tumor. III. A biochemical and genetic analysis. Am J Clin Pathol 1982;77:681-5
   PubMed Web of Science ®Google Scholar
• Weiss SW, Langloss JM, Shmookler BM, et al. Estrogen receptor protein in bone and soft tissue tumors. Lab Invest 1986;54:689-94
   PubMed Web of Science ®Google Scholar
• Maddalozzo J, Tenta LT, Hutchinson LR, et al. Juvenile fibromatosis: hormonal receptors. Int J Pediatr Otorhinolaryngol 1993;25:191-9
   PubMed Web of Science ®Google Scholar
• Lim CL, Walker MJ, Mehta RR, et al. Estrogen and antiestrogen binding sites in desmoid tumors. Eur J Cancer Clin Oncol 1986;22:583-7
   PubMedGoogle Scholar
• Picariello L, Tonelli F, Brandi ML. Selective oestrogen receptor modulators in desmoid tumours. Expert Opin Investig Drugs 2004;13:1457-68
   PubMed Web of Science ®Google Scholar
• Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. Cancer 2006;106:208-13
   PubMed Web of Science ®Google Scholar
• Santos GA, Cunha IW, Rocha RM, et al. Evaluation of estrogen receptor alpha, estrogen receptor beta, progesterone receptor, and cKIT expression in desmoids tumors and their role in determining treatment options. BioSci Trends 2010;4:25-30
   PubMed Web of Science ®Google Scholar
• Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999;17:158-67
   PubMed Web of Science ®Google Scholar
• Stojadinovic A, Leung DH, Hoos A, et al. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg 2002;235:424-34
   PubMed Web of Science ®Google Scholar
• Gronchi A, Casali PG, Mariani L, et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol 2005;23:96-104
   PubMed Web of Science ®Google Scholar
• Goy BW, Lee SP, Eilber F, et al. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. Int J Radiat Oncol Biol Phys 1997;39:659-65
   PubMed Web of Science ®Google Scholar
• Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008;34:462-8
   PubMed Web of Science ®Google Scholar
• Spear MA, Jennings LC, Mankin HJ, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys 1998;40:637-45
   PubMed Web of Science ®Google Scholar
• Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 2003;21:1390-7
   PubMed Web of Science ®Google Scholar
• Merchant NB, Lewis JJ, Woodruff JM, et al. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 1999;86:2045-52
   PubMed Web of Science ®Google Scholar
• Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 2011;29:3553-8
   PubMed Web of Science ®Google Scholar
• Stoeckle E, Coindre JM, Longy M, et al. A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. Eur J Surg Oncol 2009;35:129-34
   PubMed Web of Science ®Google Scholar
• Rock MG, Pritchard DJ, Reiman HM, et al. Extra-abdominal desmoid tumors. J Bone Joint Surg Am 1984;66:1369-74
   PubMedGoogle Scholar
• Wilkinson MJ, Chan KE, Hayes A, et al. Surgical Outcomes following Resection for Sporadic Abdominal Wall Fibromatosis. Ann Surg Oncol 2014;21(7):2144-9
   PubMed Web of Science ®Google Scholar
• Nuyttens JJ, Rust PF, Thomas CR Jr, et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer 2000;88:1517-23
   PubMed Web of Science ®Google Scholar
• Baumert BG, Spahr MO, Von Hochstetter A, et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network. Radiat Oncol 2007;2:12
   PubMed Web of Science ®Google Scholar
• Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys 2008;71:441-7
   PubMed Web of Science ®Google Scholar
• Gluck I, Griffith KA, Biermann JS, et al. Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 2011;80:787-92
   PubMed Web of Science ®Google Scholar
• Keus RB, Nout RA, Blay JY, et al. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998). Ann Oncol 2013;24:2672-6
   PubMed Web of Science ®Google Scholar
• Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007;25:1785-91
   PubMed Web of Science ®Google Scholar
• Waddell WR, Gerner RE. Indomethacin and ascorbate inhibit desmoid tumors. J Surg Oncol 1980;15:85-90
   PubMed Web of Science ®Google Scholar
• Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52
   PubMed Web of Science ®Google Scholar
• Gurpinar E, Grizzle WE, Piazza GA. NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res 2014;20:1104-13
   PubMed Web of Science ®Google Scholar
• Lanari A. Effect of progesterone on desmoid tumors (aggressive fibromatosis). N Engl J Med 1983;309:1523
   PubMed Web of Science ®Google Scholar
• Brooks MD, Ebbs SR, Colletta AA, et al. Desmoid tumours treated with triphenylethylenes. Eur J Cancer 1992;28A:1014-18
   PubMed Web of Science ®Google Scholar
• Waddell WR, Kirsch WM. Testolactone, sulindac, warfarin, and vitamin K1 for unresectable desmoid tumors. Am J Surg 1991;161:416-21
   PubMed Web of Science ®Google Scholar
• Tonelli F, Ficari F, Valanzano R, et al. Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumori 2003;89:391-6
   PubMed Web of Science ®Google Scholar
• Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004;100:612-20
   PubMed Web of Science ®Google Scholar
• Skapek SX, Anderson JR, Hill DA, et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) phase II study. Pediatr Blood Cancer 2013;60:1108-12
   PubMed Web of Science ®Google Scholar
• Bocale D, Rotelli MT, Cavallini A, et al. Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Dis 2011;13:e388-95
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47
   PubMed Web of Science ®Google Scholar
• de Camargo VP, Keohan ML, D’Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 2010;116:225-65
   Web of Science ®Google Scholar
• Sakorafas GH, Nissotakis C, Peros G. Abdominal desmoid tumors. Surg Oncol 2007;16:131-42
   PubMed Web of Science ®Google Scholar
• Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer 1993;72:3244-7
   PubMed Web of Science ®Google Scholar
• Gega M, Yanagi H, Yoshikawa R, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006;24:102-5
   PubMed Web of Science ®Google Scholar
• Costa LA, da Costa AA, Cezana L, et al. Clinical outcomes of patients with desmoid tumors treated with dacarbazine plus doxorubicin regimen. J Clin Oncol 2010;28(Suppl):abstract e20524
   Google Scholar
• Weiss AJ, Lackman RD. Low-dose chemotherapy of desmoid tumors. Cancer 1989;64:1192-4
   PubMed Web of Science ®Google Scholar
• Skapek SX, Hawk BJ, Hoffer FA, et al. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol 1998;16:3021-7
   PubMed Web of Science ®Google Scholar
• Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001;92:1259-64
   PubMed Web of Science ®Google Scholar
• Shapek SX, Ferguson WS, Granowetter L, et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol 2007;25:501-6
   PubMed Web of Science ®Google Scholar
• Weiss AJ, Horowitz S, Lackman RD. Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol 1999;22:193-5
   PubMed Web of Science ®Google Scholar
• Montgomery C, Emory C, Adams S, et al. Treatment of extra - abdominal desmoid tumors with chemotherapy. Cancers (Basel) 2011;3:3394-404
   PubMedGoogle Scholar
• Constantinidou A, Jones RL, Scurr M, et al. Advanced aggressive fibromatosis: effective palliation with chemotherapy. Acta Oncol 2011;50:455-61
   PubMed Web of Science ®Google Scholar
• Wehl G, Rossler J, Otten JE, et al. Response of progressive fibromatosis to therapy with liposomal doxorubicin. Onkologie 2004;27:552-6
   PubMed Web of Science ®Google Scholar
• Constantinidou A, Jones RL, Scurr M, et al. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer 2009;45:2930-4
   PubMed Web of Science ®Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, et al. E fficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80
   PubMed Web of Science ®Google Scholar
• Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-91
   PubMed Web of Science ®Google Scholar
• Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 2010;16:4884-91
   PubMed Web of Science ®Google Scholar
• Skubitz KM, Manivel JC, Clohisy DR, et al. Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors. Cancer Chemother Pharmacol 2009;64:635-40
   PubMed Web of Science ®Google Scholar
• Jo JC, Hong YS, Kim KP, et al. A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Invest New Drugs 2014;32:369-76
   PubMed Web of Science ®Google Scholar
• Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011;17:4082-90
   PubMed Web of Science ®Google Scholar
• Martin-Liberal J, Benson C, McCarty H, et al. Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis. Clin Sarcoma Res 2013;3:13
   PubMedGoogle Scholar
• Van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86
   PubMed Web of Science ®Google Scholar
• Nishida Y, Tsukushi S, Shido Y, et al. Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoidtumors: a pilot study. J Clin Oncol 2010;28:e107-9
   PubMed Web of Science ®Google Scholar
• Hamada S, Urakawa H, Kozawa E, et al. Nuclear expression of beta-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoidtumors. Tumour Biol 2014;35:4561-6
   PubMedGoogle Scholar
• Benson C, Judson I. Role of expert centres in the management of sarcomas – A UK perspective. Eur J Cancer 2014;50:1951-6
   PubMed Web of Science ®Google Scholar
• Casali PG. Rare cancers: work in progress in Europe. Ann Oncol 2014;25:914
   PubMed Web of Science ®Google Scholar
• Schnitzler M, Cohen Z, Blackstein M, et al. Chemotherapy for desmoid tumors in association with familial adenomatous polyposis. Dis Colon Rectum 1997;40:798-801
   PubMed Web of Science ®Google Scholar
• Okuno SH, Edmonson JH. Combination chemotherapy for desmoid tumors. Cancer 2003;97:1134-5
   PubMed Web of Science ®Google Scholar
• Reich S, Overberg-Schmidt US, Bührer C, et al. Low-dose chemotherapy with vinblastine and methotrexate in childhood desmoid tumors. J Clin Oncol 1999;17:1086
   PubMed Web of Science ®Google Scholar
• Tsukada K, Church JM, Jagelman DG, et al. Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum 1992;35:29-33
   PubMed Web of Science ®Google Scholar